Ultragenyx Pharmaceutical Inc. (RARE) Income Statement Analysis

See more : Lot78, Inc. (LOTE) Income Statement Analysis – Financial Results

Complete financial analysis of Ultragenyx Pharmaceutical Inc. (RARE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ultragenyx Pharmaceutical Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Santacruz Silver Mining Ltd. (SZSMF) Income Statement Analysis – Financial Results
Lyka Labs Limited (LYKALABS.BO) Income Statement Analysis – Financial Results
Candy Club Holdings Limited (CLB.AX) Income Statement Analysis – Financial Results
Asia Fiber Public Company Limited (AFC.BK) Income Statement Analysis – Financial Results
Lite Access Technologies Inc. (LTCCF) Income Statement Analysis – Financial Results

Ultragenyx Pharmaceutical Inc. (RARE)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.ultragenyx.com

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	434.25M	363.33M	351.41M	271.03M	103.71M	51.50M	2.61M	133.00K	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	45.21M	28.32M	16.01M	6.13M	9.01M	1.15M	1.00K	183.20M	1.38M	0.00	0.00	0.00	0.00
Gross Profit	389.04M	335.01M	335.40M	264.90M	94.71M	50.35M	2.61M	-183.07M	-1.38M	0.00	0.00	0.00	0.00
Gross Profit Ratio	89.59%	92.21%	95.44%	97.74%	91.31%	97.77%	99.96%	-137,647.37%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	648.45M	705.79M	497.15M	412.08M	357.36M	294.00M	231.64M	183.20M	114.74M	45.97M	27.83M	12.64M	4.72M
General & Administrative	0.00	0.00	0.00	0.00	0.00	127.72M	99.91M	64.94M	33.00M	10.81M	4.45M	3.34M	1.84M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	309.80M	278.14M	219.98M	182.93M	161.52M	127.72M	99.91M	64.94M	33.00M	10.81M	4.45M	3.34M	1.84M
Other Expenses	0.00	9.51M	241.00K	7.65M	12.45M	3.95M	10.60M	2.17M	-200.00K	-3.02M	-3.01M	-350.00K	-22.00K
Operating Expenses	958.25M	983.93M	717.14M	595.02M	518.88M	421.72M	331.55M	248.14M	147.74M	56.78M	32.28M	15.99M	6.56M
Cost & Expenses	1.00B	1.01B	733.14M	601.15M	527.89M	422.87M	331.55M	248.14M	147.74M	56.78M	32.28M	15.99M	6.56M
Interest Income	26.69M	11.07M	1.93M	7.04M	13.24M	9.54M	4.07M	3.79M	2.32M	608.00K	216.00K	1.00K	4.00K
Interest Expense	66.00M	43.02M	29.42M	33.29M	1.14M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	270.00K
Depreciation & Amortization	26.01M	18.20M	13.24M	12.26M	8.54M	19.54M	5.83M	3.42M	1.38M	684.00K	444.00K	313.00K	34.00K
EBITDA	-516.45M	-640.51M	-410.32M	-139.81M	-389.77M	-177.56M	-312.51M	-244.58M	-146.35M	-56.09M	-34.63M	-16.02M	-6.55M
EBITDA Ratio	-118.93%	-175.99%	-108.56%	-118.98%	-396.98%	-1,051.94%	-12,593.49%	-186,471.43%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-569.21M	-648.92M	-381.74M	-330.12M	-424.17M	-371.37M	-328.94M	-248.01M	-147.74M	-56.78M	-32.28M	-15.99M	-6.56M
Operating Income Ratio	-131.08%	-178.60%	-108.63%	-121.80%	-408.98%	-721.18%	-12,593.49%	-186,471.43%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-39.26M	-52.81M	-71.24M	144.76M	24.73M	174.28M	10.60M	2.17M	2.12M	-3.02M	-2.79M	-349.00K	-288.00K
Income Before Tax	-608.46M	-701.73M	-452.98M	-185.36M	-399.44M	-197.10M	-318.34M	-245.84M	-145.62M	-59.80M	-35.07M	-16.33M	-6.85M
Income Before Tax Ratio	-140.12%	-193.14%	-128.91%	-68.39%	-385.14%	-382.75%	-12,187.52%	-184,841.35%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-1.83M	5.70M	1.04M	1.21M	3.28M	514.00K	-16.20M	35.00K	-2.32M	-684.00K	-3.01M	-350.00K	248.00K
Net Income	-606.64M	-707.42M	-454.03M	-186.57M	-402.73M	-197.61M	-302.14M	-245.87M	-145.62M	-59.80M	-35.07M	-16.33M	-6.85M
Net Income Ratio	-139.70%	-194.71%	-129.20%	-68.84%	-388.31%	-383.75%	-11,567.34%	-184,867.67%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-8.25	-10.12	-6.70	-3.07	-7.12	-3.97	-7.12	-6.21	-3.96	-2.08	-1.21	-0.71	-0.30
EPS Diluted	-8.25	-10.12	-6.70	-3.07	-7.12	-3.97	-7.12	-6.21	-3.96	-2.08	-1.21	-0.71	-0.30
Weighted Avg Shares Out	73.54M	69.91M	67.80M	60.85M	56.58M	49.78M	42.45M	39.59M	36.78M	28.76M	29.06M	23.06M	23.06M
Weighted Avg Shares Out (Dil)	73.54M	69.91M	67.80M	60.85M	56.58M	49.78M	42.45M	39.59M	36.78M	28.76M	29.06M	23.06M	23.06M

HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT

December 3, 2024prnewswire.com

PLYMOUTH MEETING, Pa. , Dec. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming Oppenheimer Movers in Rare Disease Summit in New York, NY...

Ultragenyx to Participate in Investor Conferences in December

November 26, 2024globenewswire.com

NOVATO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 20, 2024globenewswire.com

NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 20,820 restricted stock units of...

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

November 14, 2024prnewswire.com

MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA® as the First Potential Treatment tor IgG4-RD Phase 4 AGILE Data Support Shortening KRYSTEXXA® Infusion Time THOUSAND OAKS, Calif. , Nov. 14, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of...

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

November 12, 2024seekingalpha.com

Ultragenyx's strong Q3 earnings report, with a 42% YoY revenue increase, has reignited my interest in initiating a starter position in RARE. The company's promising pipeline, including late-stage programs like Setrusumab and DTX401, presents multiple catalysts for future growth and...